Trials 10
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT00003548 | Aug 1998 → Dec 2001 | cancer | NYU Langone Health | Completed | No outcome recorded |
| Phase 1 | NCT00251368 | Jan 1995 → Sep 2007 | acute lymphoblastic leukemia, acute myeloid leukemia | Dana-Farber Cancer Institute | Completed | No outcome recorded |
| Phase 28 trials | ||||||
| Phase 2 | NCT00003523 | Jan 1999 → Oct 2007 | ovarian cancer, primary peritoneal carcinoma | Gynecologic Oncology Group | Completed | No outcome recorded |
| Phase 2 | NCT00003551 | Aug 1998 → Sep 2004 | kidney cancer | Emory University | Completed | No outcome recorded |
| Phase 2 | NCT00003192 | Mar 1998 → Feb 2002 | esophageal cancer, gastric cancer | University of Chicago | Completed | No outcome recorded |
| Phase 2 | NCT00003154 | Jan 1998 → Apr 2001 | lung cancer | Case Comprehensive Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT00002745 | Apr 1996 → Apr 2003 | lymphoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT00002671 | Dec 1995 → Feb 2001 | ovarian carcinoma | NYU Langone Health | Completed | No outcome recorded |
| Phase 2 | NCT00002635 | May 1995 → Apr 2000 | lymphoma | Yale University | Completed | No outcome recorded |
| Phase 2 | NCT00001427 | Jan 1995 → Apr 2000 | ovarian cancer | National Cancer Institute (NCI) | Completed | No outcome recorded |
Evidence & citations 10 cited values
Every value below carries the sentence it was read from. 13 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 9-aminocamptothecin | “PURPOSE: To evaluate the efficacy and toxicity of the topoisomerase I inhibitor, 9-aminocamptothecin (9-AC), in patients with relapsed lymphoma and to correlate 9-AC plasma...” PMID 18648813 ↗ Jul 2008 |
| Known as | 9-AC | “PURPOSE: To evaluate the efficacy and toxicity of the topoisomerase I inhibitor, 9-aminocamptothecin (9-AC), in patients with relapsed lymphoma and to correlate 9-AC plasma...” PMID 18648813 ↗ Jul 20086“Patients receive intraperitoneal aminocamptothecin colloidal dispersion (9-AC) over 30-60 minutes in 6 applications over a 12 day period (days 1, 3, 5, 8, 10, and 12). Courses...” NCT00003548 ↗ “This is a Phase II study of 9-aminocamptothecin (9-AC), administered as an intravenous continuous infusion over 72 hours with G-CSF support for patients with advanced...” NCT00001427 ↗ “Evaluation of Aminocamptothecin (9-AC, NSC #603071) in Recurrent, Platinum Resistant and Refractory Ovarian Cancer and Primary Peritoneal Carcinoma” NCT00003523 ↗ “A Phase II Study of 9-Amino-20(S)-Camptothecin (9-AC) (NSC 603071) and Evaluation of Drug Resistance in Patients With Advanced Renal Cell Carcinoma” NCT00003551 ↗ “Aminocamptothecin, 9-AC, NSC-603071.” NCT00002635 ↗ “9-Aminocamptothecin (9-AC)” NCT00251368 ↗ |
| Known as | 9-AC/DMA | “PHASE II STUDY OF 9-AMINOCAMPTOTHECIN (9-AC/DMA, NSC# 603071) IN PREVIOUSLY TREATED HODGKIN'S DISEASE AND NON-HODGKIN'S LYMPHOMA: IWF GRADES A-H” NCT00002745 ↗ |
| Known as | 9-Amino-20(S)-Camptothecin | “Phase I Study of Intraperitoneal Administration of 9-Amino-20(S)-Camptothecin to Patients With Cancer Predominantly Confined to the Peritoneal Cavity” NCT00003548 ↗1“A Phase II Study of 9-Amino-20(S)-Camptothecin (9-AC) (NSC 603071) and Evaluation of Drug Resistance in Patients With Advanced Renal Cell Carcinoma” NCT00003551 ↗ |
| Known as | aminocamptothecin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00002671 ↗ |
| Known as | NSC #603071 | “Evaluation of Aminocamptothecin (9-AC, NSC #603071) in Recurrent, Platinum Resistant and Refractory Ovarian Cancer and Primary Peritoneal Carcinoma” NCT00003523 ↗3“A Phase II Study of 9-Amino-20(S)-Camptothecin (9-AC) (NSC 603071) and Evaluation of Drug Resistance in Patients With Advanced Renal Cell Carcinoma” NCT00003551 ↗ “PHASE II STUDY OF 9-AMINOCAMPTOTHECIN (9-AC/DMA, NSC# 603071) IN PREVIOUSLY TREATED HODGKIN'S DISEASE AND NON-HODGKIN'S LYMPHOMA: IWF GRADES A-H” NCT00002745 ↗ “Aminocamptothecin, 9-AC, NSC-603071.” NCT00002635 ↗ |
| Action | Inhibit | “novel topoisomerase I inhibitor 9-aminocamptothecin (9-AC)” PMID 14701774 ↗ Jan 20041“DNA topoisomerase I inhibitor” CHEMBL274070 ↗ |
| Modality | Small molecule | — CHEMBL274070 ↗ |
| Route | Intravenous | “administered as an intravenous continuous infusion over 72 hours” NCT00001427 ↗ |
| Target | TOP1 | “DNA topoisomerase I inhibitor” CHEMBL274070 ↗ |